Recombinant Rat Phosphatidylcholine:ceramide cholinephosphotransferase 2 (Sgms2)

Definition and Nomenclature

Phosphatidylcholine:ceramide cholinephosphotransferase 2 (Sgms2), also known as Sphingomyelin Synthase 2, is an enzyme that catalyzes the reversible transfer of phosphocholine from phosphatidylcholine to ceramide, resulting in the formation of sphingomyelin and diacylglycerol . This enzyme is classified under EC 2.7.8.27 and represents one of the two functional sphingomyelin synthases identified in mammals, the other being Sphingomyelin Synthase 1 (Sgms1) .

Physical and Biochemical Properties

As a recombinant protein, rat Sgms2 is typically stored in a Tris-based buffer with 50% glycerol to maintain stability . The recommended storage conditions are -20°C for regular use and -20°C to -80°C for extended storage. Repeated freezing and thawing should be avoided, and working aliquots can be stored at 4°C for up to one week . The protein exhibits optimal activity at physiological pH and temperature.

Catalytic Mechanism

Sgms2 functions as a bidirectional transferase that catalyzes two main reactions:

1. Forward reaction: Transfers the phosphocholine head group from phosphatidylcholine (PC) to ceramide (CER), producing sphingomyelin (SM) and diacylglycerol (DAG) as a by-product .

2. Reverse reaction: Transfers phosphocholine from sphingomyelin to diacylglycerol, producing phosphatidylcholine and ceramide .

The direction of the reaction is largely dependent on the relative concentrations of ceramide and diacylglycerol in the membrane . Importantly, Sgms2 does not utilize free phosphorylcholine or CDP-choline as donors, requiring phospholipids with two fatty chains on the choline-phosphate donor molecule for efficient substrate recognition .

Substrate Specificity

Sgms2 exhibits specific substrate preferences. Studies have shown that it efficiently recognizes phosphatidylcholine as a substrate but can also use sphingomyelin itself as a donor of the phosphocholine group . Interestingly, Sgms2 can also transfer the phosphoethanolamine head group from phosphatidylethanolamine (PE) to ceramide, forming ceramide phosphoethanolamine (CPE) .

Research has demonstrated that non-choline phospholipids such as phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidic acid (PA), and phosphatidylglycerol (PG) are not utilized as substrates for sphingomyelin formation .

Cellular Localization and Function

While Sgms1 is primarily localized in the Golgi apparatus, Sgms2 primarily contributes to sphingomyelin synthesis and homeostasis at the plasma membrane . This differential localization suggests distinct physiological roles for the two sphingomyelin synthases.

Sgms2 regulates receptor-mediated signal transduction through multiple mechanisms:

• Modulating levels of mitogenic diacylglycerol

• Influencing proapoptotic ceramide

• Maintaining sphingomyelin levels in membrane rafts that serve as platforms for signal transduction and protein sorting

Additionally, Sgms2 plays a role in secretory transport via regulation of the diacylglycerol pool at the Golgi apparatus and its downstream effects on protein kinase D1 (PRKD1) .

Expression Systems

Recombinant rat Sgms2 can be produced using various expression systems. The following table summarizes common expression platforms used for producing this protein:

The choice of expression system depends on the intended application and the specific requirements for protein activity and modifications .

Purification Methods

Purification of recombinant rat Sgms2 typically involves several steps:

1. Cell lysis to release the protein

2. Affinity chromatography using tags determined during the production process

3. Protein G purification for antibody applications

4. Quality control to ensure >95% purity

For optimal results, the protein is often maintained in a Tris-based buffer with 50% glycerol during and after purification .

Quality Control and Validation

Quality control of recombinant rat Sgms2 involves:

• Verification of protein identity through mass spectrometry or Western blotting

• Assessment of purity through SDS-PAGE

• Functional assays to confirm enzymatic activity

• Validation of applications such as ELISA, Western blot, and immunohistochemistry

These quality control measures ensure that the recombinant protein meets the necessary standards for research applications .

ELISA Kits

ELISA kits utilizing recombinant rat Sgms2 are valuable tools for quantitative measurement of Sgms2 in various biological samples. Based on available data, these kits typically offer the following specifications:

The procedure for these ELISA kits typically involves:

1. Sample preparation according to the source material

2. Incubation with capture antibodies

3. Addition of detection antibodies and enzyme conjugates

4. Colorimetric detection and measurement at 450nm

Antibodies Against Rat Sgms2

Several antibodies against rat Sgms2 are available for research purposes. These include:

These antibodies serve as valuable tools for detecting and studying Sgms2 in various experimental contexts .

Functional Studies

Recombinant rat Sgms2 has been instrumental in various functional studies investigating:

• Enzymatic mechanisms of sphingomyelin synthesis

• Structure-function relationships of sphingomyelin synthases

• Roles of Sgms2 in cellular signaling pathways

• Effects of Sgms2 modulation on disease models

These studies have provided valuable insights into the physiological roles of Sgms2 and its potential as a therapeutic target .

Bone Development and Metabolism

Sgms2 plays a critical role in bone development and metabolism. Studies have shown high expression of Sgms2 in cortical bone, vertebrae, kidney, and liver in murine models . In vitro studies have demonstrated that murine osteoblasts, bone marrow macrophages, and osteoclasts express Sgms2 at similar levels .

The importance of Sgms2 in bone development is underscored by the finding that pathogenic variants in human SGMS2 cause a rare skeletal disorder characterized by calvarial doughnut lesions with bone fragility (CDL) . This condition is associated with low bone mineral density, neonatal fractures, long-bone deformities, and short stature.

The relationship between Sgms2 and bone metabolism appears to involve:

• Regulation of osteoblast function and bone matrix mineralization

• Potential influences on osteoclastogenesis through the 1,25(OH)₂D pathway

• Effects on cellular lipid distributions crucial for bone formation

Neurological Functions

In addition to skeletal effects, Sgms2 has important neurological functions. Patients with SGMS2 mutations often experience neurological manifestations, particularly transitory, spontaneously resolving, and recurrent cranial nerve palsies, with facial nerve palsy being the most common .

The neurological role of Sgms2 likely relates to:

• Sphingomyelin's importance in myelin sheaths that insulate nerve fibers

• Regulation of lipid rafts that serve as platforms for neuronal signaling

• Potential influences on neuronal apoptosis through modulation of ceramide levels

These neurological manifestations highlight the diverse physiological roles of Sgms2 beyond bone metabolism .

Other Physiological Functions

Sgms2 is involved in various other physiological processes, including:

• Cell growth regulation

• Apoptosis modulation

• Inflammatory responses

• Respiratory function

In a study of airway resistance, Sgms2 knockout mice showed greater AKT phosphorylation, peribronchial collagen deposition, and protease activity in their lungs after smoke inhalation, suggesting a protective role of Sgms2 in respiratory health . These diverse functions reflect the importance of proper sphingolipid metabolism in multiple physiological systems.

SGMS2-Related Osteoporosis

Pathogenic variants in the SGMS2 gene cause a rare form of osteoporosis with distinct clinical features. The table below summarizes the known pathogenic variants and their associated phenotypes:

Interestingly, these pathogenic variants do not necessarily reduce the enzymatic activity of Sgms2, but rather affect its subcellular localization . The missense variants cause retention of the enzyme in the endoplasmic reticulum due to disruption of an ER export signal, while the p.Arg50* variant is predicted to result in a truncated enzyme lacking the entire transmembrane helices and active sites .

Cancer and Metastasis

Sgms2 has been implicated in cancer progression and metastasis. A study on breast cancer demonstrated that high SGMS2 expression is associated with breast cancer metastasis . Functional assays revealed that SGMS2:

• Promotes cancer cell proliferation by suppressing apoptosis through a ceramide-associated pathway

• Enhances cancer cell invasiveness by promoting epithelial-to-mesenchymal transition (EMT) through the TGF-β/Smad signaling pathway

• Activates the TGF-β/Smad signaling pathway by increasing TGF-β1 secretion

These findings suggest that Sgms2 may be a potential therapeutic target for breast cancer treatment.

Respiratory Disorders

Studies have also implicated Sgms2 in respiratory disorders. Sgms2 knockout mice exhibited greater AKT phosphorylation, peribronchial collagen deposition, and protease activity in their lungs after smoke inhalation . Similar changes were observed in human bronchial epithelial cells isolated from subjects with chronic obstructive pulmonary disease (COPD), which showed reduced SGMS2 expression and enhanced phosphorylation of AKT and protease production .

Selective inhibition of AKT activity or overexpression of SGMS2 reduced the production of matrix metalloproteinases in bronchial epithelial cells and monocyte-derived macrophages, suggesting potential therapeutic approaches for COPD targeting this pathway .

Sequence Homology and Conservation

Rat Sgms2 shares significant sequence homology with human SGMS2. Comparative analysis reveals high conservation of key functional domains, particularly:

• The N-terminal region containing the ER export signal

• Transmembrane domains

• Catalytic sites responsible for enzymatic activity

This conservation is especially pronounced in the region immediately upstream of the first transmembrane domain (TMD1), which contains the IXMP motif that functions as an ER export signal . The conservation extends across various species, including mouse and zebrafish, highlighting the evolutionary importance of this protein.

Functional Comparison

Both rat Sgms2 and human SGMS2 function primarily as sphingomyelin synthases at the plasma membrane. They catalyze the bidirectional transfer of phosphocholine between phosphatidylcholine and ceramide, and both can also transfer phosphoethanolamine to form ceramide phosphoethanolamine .

The subcellular localization patterns are also similar, with both proteins primarily localizing to the plasma membrane with some presence in the Golgi apparatus. This similarity in function and localization makes rat Sgms2 a valuable model for studying human SGMS2 in both normal physiology and pathological conditions .

Therapeutic Potential

The involvement of Sgms2 in various pathological conditions suggests several potential therapeutic applications:

1. For SGMS2-related osteoporosis:

   • Development of therapies targeting proper trafficking of mutant SGMS2 proteins

   • Approaches to correct lipid distributions in osteogenic cells

2. For cancer treatment:

   • SGMS2 inhibitors to modulate ceramide levels and promote apoptosis in cancer cells

   • Therapies targeting the SGMS2-mediated TGF-β/Smad signaling pathway

3. For respiratory disorders:

   • SGMS2 activators or overexpression strategies to reduce protease activity and inflammation

These therapeutic approaches require further research to understand the precise mechanisms of Sgms2 in these pathological conditions .

Research Challenges and Opportunities

Despite significant advances, several challenges remain in Sgms2 research:

• Determining the three-dimensional structure of the protein

• Understanding the precise mechanisms of substrate recognition and catalysis

• Elucidating the regulation of Sgms2 expression in different tissues

• Developing specific inhibitors or activators for therapeutic purposes

• Investigating the potential of Sgms2 as a biomarker for disease diagnosis or prognosis

Addressing these challenges presents opportunities for innovative research approaches, including:

• Advanced imaging techniques to study Sgms2 localization and trafficking

• CRISPR-Cas9 technology to generate and study Sgms2 variants

• Lipidomic approaches to understand the broader impact of Sgms2 on cellular lipid profiles

• Development of cell and animal models to study Sgms2-related diseases

Definition and Nomenclature

Phosphatidylcholine:ceramide cholinephosphotransferase 2 (Sgms2), also known as Sphingomyelin Synthase 2, is an enzyme that catalyzes the reversible transfer of phosphocholine from phosphatidylcholine to ceramide, resulting in the formation of sphingomyelin and diacylglycerol . This enzyme is classified under EC 2.7.8.27 and represents one of the two functional sphingomyelin synthases identified in mammals, the other being Sphingomyelin Synthase 1 (Sgms1) .

Physical and Biochemical Properties

As a recombinant protein, rat Sgms2 is typically stored in a Tris-based buffer with 50% glycerol to maintain stability . The recommended storage conditions are -20°C for regular use and -20°C to -80°C for extended storage. Repeated freezing and thawing should be avoided, and working aliquots can be stored at 4°C for up to one week . The protein exhibits optimal activity at physiological pH and temperature.

Catalytic Mechanism

Sgms2 functions as a bidirectional transferase that catalyzes two main reactions:

1. Forward reaction: Transfers the phosphocholine head group from phosphatidylcholine (PC) to ceramide (CER), producing sphingomyelin (SM) and diacylglycerol (DAG) as a by-product .

2. Reverse reaction: Transfers phosphocholine from sphingomyelin to diacylglycerol, producing phosphatidylcholine and ceramide .

The direction of the reaction is largely dependent on the relative concentrations of ceramide and diacylglycerol in the membrane . Importantly, Sgms2 does not utilize free phosphorylcholine or CDP-choline as donors, requiring phospholipids with two fatty chains on the choline-phosphate donor molecule for efficient substrate recognition .

Substrate Specificity

Sgms2 exhibits specific substrate preferences. Studies have shown that it efficiently recognizes phosphatidylcholine as a substrate but can also use sphingomyelin itself as a donor of the phosphocholine group . Interestingly, Sgms2 can also transfer the phosphoethanolamine head group from phosphatidylethanolamine (PE) to ceramide, forming ceramide phosphoethanolamine (CPE) .

Research has demonstrated that non-choline phospholipids such as phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidic acid (PA), and phosphatidylglycerol (PG) are not utilized as substrates for sphingomyelin formation .

Cellular Localization and Function

While Sgms1 is primarily localized in the Golgi apparatus, Sgms2 primarily contributes to sphingomyelin synthesis and homeostasis at the plasma membrane . This differential localization suggests distinct physiological roles for the two sphingomyelin synthases.

Sgms2 regulates receptor-mediated signal transduction through multiple mechanisms:

• Modulating levels of mitogenic diacylglycerol

• Influencing proapoptotic ceramide

• Maintaining sphingomyelin levels in membrane rafts that serve as platforms for signal transduction and protein sorting

Additionally, Sgms2 plays a role in secretory transport via regulation of the diacylglycerol pool at the Golgi apparatus and its downstream effects on protein kinase D1 (PRKD1) .

Expression Systems

Recombinant rat Sgms2 can be produced using various expression systems. The following table summarizes common expression platforms used for producing this protein:

The choice of expression system depends on the intended application and the specific requirements for protein activity and modifications .

Purification Methods

Purification of recombinant rat Sgms2 typically involves several steps:

1. Cell lysis to release the protein

2. Affinity chromatography using tags determined during the production process

3. Protein G purification for antibody applications

4. Quality control to ensure >95% purity

For optimal results, the protein is often maintained in a Tris-based buffer with 50% glycerol during and after purification .

Quality Control and Validation

Quality control of recombinant rat Sgms2 involves:

• Verification of protein identity through mass spectrometry or Western blotting

• Assessment of purity through SDS-PAGE

• Functional assays to confirm enzymatic activity

• Validation of applications such as ELISA, Western blot, and immunohistochemistry

These quality control measures ensure that the recombinant protein meets the necessary standards for research applications .

ELISA Kits

ELISA kits utilizing recombinant rat Sgms2 are valuable tools for quantitative measurement of Sgms2 in various biological samples. Based on available data, these kits typically offer the following specifications:

The procedure for these ELISA kits typically involves:

1. Sample preparation according to the source material

2. Incubation with capture antibodies

3. Addition of detection antibodies and enzyme conjugates

4. Colorimetric detection and measurement at 450nm

Antibodies Against Rat Sgms2

Several antibodies against rat Sgms2 are available for research purposes. These include:

These antibodies serve as valuable tools for detecting and studying Sgms2 in various experimental contexts .

Functional Studies

Recombinant rat Sgms2 has been instrumental in various functional studies investigating:

• Enzymatic mechanisms of sphingomyelin synthesis

• Structure-function relationships of sphingomyelin synthases

• Roles of Sgms2 in cellular signaling pathways

• Effects of Sgms2 modulation on disease models

These studies have provided valuable insights into the physiological roles of Sgms2 and its potential as a therapeutic target .

Bone Development and Metabolism

Sgms2 plays a critical role in bone development and metabolism. Studies have shown high expression of Sgms2 in cortical bone, vertebrae, kidney, and liver in murine models . In vitro studies have demonstrated that murine osteoblasts, bone marrow macrophages, and osteoclasts express Sgms2 at similar levels .

The importance of Sgms2 in bone development is underscored by the finding that pathogenic variants in human SGMS2 cause a rare skeletal disorder characterized by calvarial doughnut lesions with bone fragility (CDL) . This condition is associated with low bone mineral density, neonatal fractures, long-bone deformities, and short stature.

The relationship between Sgms2 and bone metabolism appears to involve:

• Regulation of osteoblast function and bone matrix mineralization

• Potential influences on osteoclastogenesis through the 1,25(OH)₂D pathway

• Effects on cellular lipid distributions crucial for bone formation

Neurological Functions

In addition to skeletal effects, Sgms2 has important neurological functions. Patients with SGMS2 mutations often experience neurological manifestations, particularly transitory, spontaneously resolving, and recurrent cranial nerve palsies, with facial nerve palsy being the most common .

The neurological role of Sgms2 likely relates to:

• Sphingomyelin's importance in myelin sheaths that insulate nerve fibers

• Regulation of lipid rafts that serve as platforms for neuronal signaling

• Potential influences on neuronal apoptosis through modulation of ceramide levels

These neurological manifestations highlight the diverse physiological roles of Sgms2 beyond bone metabolism .

Other Physiological Functions

Sgms2 is involved in various other physiological processes, including:

• Cell growth regulation

• Apoptosis modulation

• Inflammatory responses

• Respiratory function

In a study of airway resistance, Sgms2 knockout mice showed greater AKT phosphorylation, peribronchial collagen deposition, and protease activity in their lungs after smoke inhalation, suggesting a protective role of Sgms2 in respiratory health . These diverse functions reflect the importance of proper sphingolipid metabolism in multiple physiological systems.

SGMS2-Related Osteoporosis

Pathogenic variants in the SGMS2 gene cause a rare form of osteoporosis with distinct clinical features. The table below summarizes the known pathogenic variants and their associated phenotypes:

Interestingly, these pathogenic variants do not necessarily reduce the enzymatic activity of Sgms2, but rather affect its subcellular localization . The missense variants cause retention of the enzyme in the endoplasmic reticulum due to disruption of an ER export signal, while the p.Arg50* variant is predicted to result in a truncated enzyme lacking the entire transmembrane helices and active sites .

Cancer and Metastasis

Sgms2 has been implicated in cancer progression and metastasis. A study on breast cancer demonstrated that high SGMS2 expression is associated with breast cancer metastasis . Functional assays revealed that SGMS2:

• Promotes cancer cell proliferation by suppressing apoptosis through a ceramide-associated pathway

• Enhances cancer cell invasiveness by promoting epithelial-to-mesenchymal transition (EMT) through the TGF-β/Smad signaling pathway

• Activates the TGF-β/Smad signaling pathway by increasing TGF-β1 secretion

These findings suggest that Sgms2 may be a potential therapeutic target for breast cancer treatment.

Respiratory Disorders

Studies have also implicated Sgms2 in respiratory disorders. Sgms2 knockout mice exhibited greater AKT phosphorylation, peribronchial collagen deposition, and protease activity in their lungs after smoke inhalation . Similar changes were observed in human bronchial epithelial cells isolated from subjects with chronic obstructive pulmonary disease (COPD), which showed reduced SGMS2 expression and enhanced phosphorylation of AKT and protease production .

Selective inhibition of AKT activity or overexpression of SGMS2 reduced the production of matrix metalloproteinases in bronchial epithelial cells and monocyte-derived macrophages, suggesting potential therapeutic approaches for COPD targeting this pathway .

Sequence Homology and Conservation

Rat Sgms2 shares significant sequence homology with human SGMS2. Comparative analysis reveals high conservation of key functional domains, particularly:

• The N-terminal region containing the ER export signal

• Transmembrane domains

• Catalytic sites responsible for enzymatic activity

This conservation is especially pronounced in the region immediately upstream of the first transmembrane domain (TMD1), which contains the IXMP motif that functions as an ER export signal . The conservation extends across various species, including mouse and zebrafish, highlighting the evolutionary importance of this protein.

Functional Comparison

Both rat Sgms2 and human SGMS2 function primarily as sphingomyelin synthases at the plasma membrane. They catalyze the bidirectional transfer of phosphocholine between phosphatidylcholine and ceramide, and both can also transfer phosphoethanolamine to form ceramide phosphoethanolamine .

The subcellular localization patterns are also similar, with both proteins primarily localizing to the plasma membrane with some presence in the Golgi apparatus. This similarity in function and localization makes rat Sgms2 a valuable model for studying human SGMS2 in both normal physiology and pathological conditions .

Therapeutic Potential

The involvement of Sgms2 in various pathological conditions suggests several potential therapeutic applications:

1. For SGMS2-related osteoporosis:

   • Development of therapies targeting proper trafficking of mutant SGMS2 proteins

   • Approaches to correct lipid distributions in osteogenic cells

2. For cancer treatment:

   • SGMS2 inhibitors to modulate ceramide levels and promote apoptosis in cancer cells

   • Therapies targeting the SGMS2-mediated TGF-β/Smad signaling pathway

3. For respiratory disorders:

   • SGMS2 activators or overexpression strategies to reduce protease activity and inflammation

These therapeutic approaches require further research to understand the precise mechanisms of Sgms2 in these pathological conditions .

Research Challenges and Opportunities

Despite significant advances, several challenges remain in Sgms2 research:

• Determining the three-dimensional structure of the protein

• Understanding the precise mechanisms of substrate recognition and catalysis

• Elucidating the regulation of Sgms2 expression in different tissues

• Developing specific inhibitors or activators for therapeutic purposes

• Investigating the potential of Sgms2 as a biomarker for disease diagnosis or prognosis

Addressing these challenges presents opportunities for innovative research approaches, including:

• Advanced imaging techniques to study Sgms2 localization and trafficking

• CRISPR-Cas9 technology to generate and study Sgms2 variants

• Lipidomic approaches to understand the broader impact of Sgms2 on cellular lipid profiles

• Development of cell and animal models to study Sgms2-related diseases